TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:24
EAGLE PHARMACEUTICALS INC. ( EGRX ) https://www.eagleus.com
5.05USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-82.07%
EGRX
SPY
32.74%
-87.90%
EGRX
SPY
92.93%
-90.00%
EGRX
SPY
224.41%
-59.14%
EGRX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
66.83
131.38
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
4.29
0.26
0.27
-51.13
0.00
2.44
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
15.94
73.92
20.73
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.1048
8.64
13.44
0.76
Other Earnings and Cash Flow Stats:
EAGLE PHARMACEUTICALS INC. ( EGRX ) Net Income TTM ($MM) is 0.37
EAGLE PHARMACEUTICALS INC. ( EGRX ) Operating Income TTM ($MM) is 19.67
EAGLE PHARMACEUTICALS INC. ( EGRX ) Owners' Earnings Annual ($MM) is -9.31
EAGLE PHARMACEUTICALS INC. ( EGRX ) Current Price to Owners' Earnings ratio is -7.13
EAGLE PHARMACEUTICALS INC. ( EGRX ) EBITDA TTM ($MM) is 25.89
EAGLE PHARMACEUTICALS INC. ( EGRX ) EBITDA Margin is 20.73%
Capital Allocation:
EAGLE PHARMACEUTICALS INC. ( EGRX ) has paid 0.00 dividends per share and bought back -0.089105 million shares in the past 12 months
EAGLE PHARMACEUTICALS INC. ( EGRX ) has increased its debt by 5.873 million USD in the last 12 months
Capital Structure:
EAGLE PHARMACEUTICALS INC. ( EGRX ) Interest-bearing Debt ($MM) as of last quarter is 79
EAGLE PHARMACEUTICALS INC. ( EGRX ) Annual Working Capital Investments ($MM) are 95
EAGLE PHARMACEUTICALS INC. ( EGRX ) Book Value ($MM) as of last quarter is 252
EAGLE PHARMACEUTICALS INC. ( EGRX ) Debt/Capital as of last quarter is 31%
Other Balance Sheet Stats:
EAGLE PHARMACEUTICALS INC. ( EGRX ) has 15 million in cash on hand as of last quarter
EAGLE PHARMACEUTICALS INC. ( EGRX ) has 86 million of liabilities due within 12 months, and long term debt 70 as of last quarter
EAGLE PHARMACEUTICALS INC. ( EGRX ) has 13 common shares outstanding as of last quarter
EAGLE PHARMACEUTICALS INC. ( EGRX ) has 0 million USD of preferred stock value
Academic Scores:
EAGLE PHARMACEUTICALS INC. ( EGRX ) Altman Z-Score is 1.93 as of last quarter
EAGLE PHARMACEUTICALS INC. ( EGRX ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
EAGLE PHARMACEUTICALS INC. ( EGRX ) largest shareholder is owning shares at 0.00 ($MM) value
Scott Tarriff(an insider) Sold 10925 shares of EAGLE PHARMACEUTICALS INC. ( EGRX ) for the amount of $150983.50 on 2023-11-01
12.56% of EAGLE PHARMACEUTICALS INC. ( EGRX ) is held by insiders, and 80.22% is held by institutions
EAGLE PHARMACEUTICALS INC. ( EGRX ) went public on 2014-02-12
Other EAGLE PHARMACEUTICALS INC. ( EGRX ) financial metrics:
FCF:66.99
Unlevered Free Cash Flow:-52.77
EPS:1.57
Operating Margin:15.94
Gross Profit Margin:73.92
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:8.20
Beta:0.76
Buffet's Owners Earnings:-9.31
Price to Owner's Earnings:-7.13
About EAGLE PHARMACEUTICALS INC. ( EGRX ) :
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.